Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib vs Sorafenib in First-line Advanced HCC
CTR20191551Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Aug 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib, sorafenib in hepatocellular carcinoma (HCC), sponsored by Hengrui Therapeutics. Started Aug 2019; status: completed.
02
Drugs
camrelizumabRivoceranibsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20191551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191551.